Improgo et al. (2019) [45] revealed that MYD88 L265P is associated with a prognostic gene expression signature, and demonstrated the potential of the MYD88 pathway as a therapeutic target in CLL through IRAK4 inhibition. The gene discussed is IRAK4; the disease is B-cell chronic lymphocytic leukemia.